GEHC
Get informed when a big investor buys or sells
+ FollowApril 29, 2026 - AI Summary
Undervalued by 78.2% based on the discounted cash flow analysis.
| Market cap | $28.02 Billion |
|---|---|
| Enterprise Value | $38.46 Billion |
| Dividend Yield | $0.14 (0.23%) |
| Earnings per Share | $4.56 |
| Beta | 0.86 |
| Outstanding Shares | 456,000,000 |
| P/E Ratio | 18.66 |
|---|---|
| PEG | -60.15 |
| Price to Sales | 1.41 |
| Price to Book Ratio | 2.64 |
| Enterprise Value to Revenue | 1.93 |
| Enterprise Value to EBIT | 17.06 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.33 |
| Debt to Equity | 1.19 |
No data
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.0412▲ 29.34% |
|---|---|
| Total Calls | 2,424,758▼ 14.97% |
| Total Puts | 2,524,750▲ 18.39% |
Holdings and activity of institutional investors.
| Ownership % | 85.18%▼ 10.75% |
|---|---|
| Total Invested | $27.61B▼ 58.66% |
| Investors Holding | 1,303▼ 66.00% |
No data
This powerful committee controls taxation, trade, and entitlement spending. It directly impacts GE HealthCare Technologies through policies related to Medicare and Medicaid reimbursement rates, corporate tax policy, and international trade tariffs.
This committee directly allocates discretionary federal spending. Its subcommittees determine the specific funding for agencies and programs (e.g., NIH, VA, Medicare/Medicaid components) that are major customers or influence the market for GE HealthCare Technologies.
This committee directly regulates the FDA, which is the primary regulatory body for GE HealthCare Technologies' medical devices and diagnostics. It also oversees NIH funding, impacting research relevant to GEHC's innovation pipeline.
GE HealthCare Technologies manufactures medical devices and solutions that are likely purchased by the Department of Veterans Affairs (VA). The committee's funding decisions directly impact GEHC's potential sales and revenue from the VA healthcare system.